Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (Rating Upgrade) [Seeking Alpha]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Seeking Alpha
Relacorilant's transition plan faltered after an FDA CRL, delaying lifecycle extension and increasing reliance on KORLYM outcomes. Oncology pipeline, especially relacorilant in ovarian cancer, offers new upside, but regulatory and commercial prospects remain fragile. With compressed net pricing, rising SG&A, and unresolved legal/regulatory risks, I remain neutral and await clearer catalysts. Bjarte Rettedal/DigitalVision via Getty Images Overview Corcept Therapeutics ( CORT ) has missed out on market gains since my last write-up in July 2024. I was “Sell” on its stock, expressing caution surrounding its lead product, KORLYM, for the treatment of Cushing syndrome (hypercortisolism). Corcept was amidst a This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opin
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens BermanGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORTPR Newswire
- Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics (NASDAQ:CORT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law FirmPR Newswire
CORT
Earnings
- 11/4/25 - Miss
CORT
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 144
- 1/5/26 - Form 4
- CORT's page on the SEC website